• 2Q23 dermal-filler sales were $31.8M, +5% QoQ and +25% YoY.
• 2Q23 “Other revenue” (OPUL services) was $3.7M.
• 2Q23 GAAP and non-GAAP operating expenses (excluding revenue and COGS) were $123.64M and $83.2M, respectively, consistent with RVNC’s prior full-year 2023 guidance of $460-480M and $320-340M, respectively.
• Cash at 6/30/23 was $319.7M, an increase of $45.8M since 3/31/23 due to selling 3.2M shares under the ATM facility at an average price of $31.25.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.